Tibet Weixinkang Medicine Co Ltd
Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of chemical drugs and their bulk drugs in China. The company offers parenteral nutrition vitamins; electrolyte supplements; intravenous iron, trace, electrolytes, and amino acids supplements; antibiotics; acetylcysteine solution for inhalation; medicine for liver diseases; and other special fields. I… Read more
Tibet Weixinkang Medicine Co Ltd (603676) - Total Liabilities
Latest total liabilities as of September 2025: CN¥382.95 Million CNY
Based on the latest financial reports, Tibet Weixinkang Medicine Co Ltd (603676) has total liabilities worth CN¥382.95 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Tibet Weixinkang Medicine Co Ltd - Total Liabilities Trend (2013–2024)
This chart illustrates how Tibet Weixinkang Medicine Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Tibet Weixinkang Medicine Co Ltd Competitors by Total Liabilities
The table below lists competitors of Tibet Weixinkang Medicine Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Blumar
SN:BLUMAR
|
Chile | CL$521.65 Million |
|
Saratoga Investama Sedaya
JK:SRTG
|
Indonesia | Rp3.68 Trillion |
|
McBride plc
PINK:MCBRF
|
USA | $398.94 Million |
|
Archer Ltd.
LSE:0RBA
|
UK | Nkr735.20 Million |
|
Shenzhen RoadRover Technology Co Ltd
SHE:002813
|
China | CN¥257.39 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Tibet Weixinkang Medicine Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tibet Weixinkang Medicine Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tibet Weixinkang Medicine Co Ltd (2013–2024)
The table below shows the annual total liabilities of Tibet Weixinkang Medicine Co Ltd from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥468.24 Million | +7.26% |
| 2023-12-31 | CN¥436.55 Million | -1.71% |
| 2022-12-31 | CN¥444.13 Million | +3.70% |
| 2021-12-31 | CN¥428.31 Million | +13.65% |
| 2020-12-31 | CN¥376.85 Million | +0.61% |
| 2019-12-31 | CN¥374.56 Million | +11.04% |
| 2018-12-31 | CN¥337.33 Million | +112.71% |
| 2017-12-31 | CN¥158.58 Million | +70.64% |
| 2016-12-31 | CN¥92.94 Million | -12.18% |
| 2015-12-31 | CN¥105.82 Million | +37.27% |
| 2014-12-31 | CN¥77.09 Million | +25.31% |
| 2013-12-31 | CN¥61.52 Million | -- |